Company Profile

Xechem International Inc (AKA: Xechem Inc)
Profile last edited on: 12/14/2015      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1990
First Award
1991
Latest Award
2006
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

379 Thornall Street
Edison, NJ 08837
   (732) 205-0500
   ramesh@xechem.com
   www.xechem.com
Location: Single
Congr. District: 06
County: Middlesx

Public Profile

Xechem International, Inc., a development stage biopharmaceutical company, engages in the research, development, and limited production of generic drugs from natural sources. The company operates primarily through its subsidiary, Xechem Inc., which engages in applying its extraction, isolation, and purification technology to the production and manufacture of paclitaxel (Taxol). Paclitaxel is an anticancer compound used for the treatment of ovarian, breast, and small cell lung cancers, as well as AIDS related Kaposi sarcomas. The company’s other products include Nicosan/Hemoxin, a nutraceutical product, which has received orphan drug designation from U.S.-FDA; Vancomycin; and Bleomycin. In addition, the company engages in the research and development of other generic compounds, by microbial fermentation or semisynthesis; and on the development of drugs from sources derived from Chinese, Indian, and other traditional medicinal plants in the anticancer, antifungal, anti-viral, anti-inflammatory, anti-aging, and memory enhancing areas.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
75-99
Revenue Range
7.5M-10M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
OTC : XKEM.PK
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 1 NIH $473,181
Project Title: Toxicity Studies of Potent Antisickling Agent 5HMF
2003 1 NIH $99,372
Project Title: Niprisan for treating patients with sickle cell disease
2000 1 NIH $97,918
Project Title: Bioactive Natural Products From Marine Extremophiles
1996 1 NIH $86,742
Project Title: Enhanced Xechem Integrated Screening Technique (EXISTTM)
1992 1 NIH $49,680
Project Title: Development of hydroheptin a antifungal antibiotic

Key People / Management

  Ramesh C Pandey -- Chief Exec. Officer

  Michael Bennett -- Primary Contact

  William H Pursley

Company News

There are no news available.